Skip to content
10-K

Annual Report

Acrivon Therapeutics, Inc. ACRV

0000950170-25-046056

← back to feed
Filed
Mar 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 24, 2025 31.35M sh
Shares Diluted FY 2024 · Dec 31, 2023 22.08M sh
Capex FY 2024 · Dec 31, 2023 $1.29M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$42.64M
Short Term Investments FY 2024 · Dec 31, 2023 $91.44M
Cash And Equivalents FY 2024 · Dec 31, 2023 $36.02M
Current Liabilities FY 2024 · Dec 31, 2023 $13.3M
Total Liabilities FY 2024 · Dec 31, 2023 $17.07M
Current Assets FY 2024 · Dec 31, 2023 $129.69M
Total Assets FY 2024 · Dec 31, 2023 $138.27M
Eps Diluted FY 2024 · Dec 31, 2023 −$2.74
Eps Basic FY 2024 · Dec 31, 2023 −$2.74
Sga Expense FY 2024 · Dec 31, 2023 $21.08M
Rd Expense FY 2024 · Dec 31, 2023 $46.02M
Net Income FY 2024 · Dec 31, 2023 −$60.39M
Operating Income FY 2024 · Dec 31, 2023 −$67.1M
Stockholders Equity FY 2024 · Dec 31, 2022 $170.48M